Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Type Condition

    Burleson, TX

    Search
    Burleson, TX
    Show Map
    Map View
    Burleson, TX
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      215 Clinical Trials near Burleson, TX

      Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Ziltivekimab for Cardiovascular Disease

      Fort Worth, Texas
      This trial is testing whether ziltivekimab can lower the risk of heart attacks and strokes in people with heart disease, kidney disease, and inflammation. Participants will inject the medicine regularly. The study aims to see if reducing inflammation can help prevent serious heart problems.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Recent Heart Attack, Recent Stroke, Others

      6200 Participants Needed

      Litifilimab for Lupus

      Mansfield, Texas
      In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants. The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the disease. The main question researchers want to answer is: \- How many participants have an improvement in their symptoms after 52 weeks of treatment? Researchers will answer this and other questions by measuring the symptoms of SLE over time using a variety of scoring tools. These include the SLE Responder Index (SRI), the Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K), and the Patient Global Assessment - Visual Analog Scale (PGA-VAS). Researchers will also learn more about the safety of litifilimab. They will study how participants' immune systems respond to litifilimab. Additionally, they will measure the effect litifilimab and SLE have on the quality of life of participants using a group of questionnaires. The study will be done as follows: * After screening, participants will be randomized to receive either a high or low dose of litifilimab, or placebo. A placebo looks like the study drug but contains no real medicine. * All participants will receive either litifilimab or placebo as injections under the skin once every 4 weeks. The treatment period will last 52 weeks. Participants will continue to take their standard of care medications. * Neither the researchers nor the participants will know if the participants are receiving litifilimab or placebo. * There will be a follow-up safety period that lasts up to 24 weeks. * In total, participants will have up to 22 study visits. The total study duration for participants will be up to 80 weeks.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis B, Hepatitis C, Others
      Must Be Taking:Antimalarials, Steroids, Immunosuppressants

      548 Participants Needed

      Lanifibranor for Nonalcoholic Steatohepatitis (NASH)

      Mansfield, Texas
      This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Chronic Liver Disease, Cirrhosis, HIV, Others
      Must Be Taking:GLP1 Receptor Agonists, SGLT2 Inhibitors

      1000 Participants Needed

      Cariprazine for Bipolar Disorder in Youth

      Mansfield, Texas
      This trial is testing the safety and effectiveness of Cariprazine for treating depressive episodes in children and teenagers with bipolar I disorder. The goal is to find out if Cariprazine can help young people with this condition. Cariprazine is an atypical antipsychotic recently approved for the treatment of depressive episodes in adults with bipolar I disorder.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:10 - 17

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Substance Disorder, Seizures, Others
      Must Not Be Taking:Psychotropics, CYP3A4 Inhibitors

      380 Participants Needed

      Benralizumab for Nasal Polyps

      Fort Worth, Texas
      This trial tests benralizumab injections in patients with severe nasal polyps who haven't responded to other treatments. The medication reduces specific cells that cause inflammation, aiming to improve symptoms. Benralizumab has been studied for its effects on severe asthma and nasal polyps.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Recent Nasal Surgery, Allergic Fungal Sinusitis, Others
      Must Be Taking:Intranasal Corticosteroids

      296 Participants Needed

      Tirzepatide vs Dulaglutide for Type 2 Diabetes

      Fort Worth, Texas
      The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:40+

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Severe Hypoglycemia, Pancreatitis, Malignancy, Others

      13299 Participants Needed

      KarXT for Bipolar Disorder

      Mansfield, Texas
      The purpose of this study is to evaluate the efficacy and safety of adjunctive KarXT for the treatment of mania in participants with Bipolar-I Disorder.
      Stay on current meds
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Suicidal Risk, Others
      Must Be Taking:Lithium, Valproate, Lamotrigine

      424 Participants Needed

      Survodutide for Fatty Liver Disease

      Mansfield, Texas
      This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with NASH or MASH improve their liver function. Participants are put into 2 groups randomly, which means by chance. 1 group gets survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Each participant has twice the chance of getting survodutide. Participants and doctors do not know who is in which group. Participants inject survodutide or placebo under their skin once a week. All participants regularly receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for up to 4 and a half years. During this time, they visit the study site or have a remote visit by video call every 2, 4 or 6 weeks for about a 1 year and 5 months. After this time participants visit the trial site or have a remote visit every 3 months until the end of the study. The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. At some visits the liver parameters are measured using different imaging methods. The participants also fill in questionnaires about their symptoms. The results are compared between the groups to see whether the treatment works.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Chronic Liver Diseases, Hepatitis B, Hepatitis C, Others

      1590 Participants Needed

      mRNA-1345 Vaccine for Respiratory Syncytial Virus

      Fort Worth, Texas
      This trial is testing a new vaccine called mRNA-1345 to see if it can prevent lung infections caused by the RSV virus. The vaccine works by teaching the body to recognize and fight the virus. The study will include people who are at risk of these infections and will compare the effects of the vaccine to a non-treatment group.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2, 3
      Age:60+

      Key Eligibility Criteria

      Disqualifiers:Guillain-Barré, Other Vaccines, Others

      36814 Participants Needed

      Vedolizumab + Tofacitinib for Ulcerative Colitis

      Mansfield, Texas
      The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim is to learn about treatment with Vedolizumab alone after the double treatment. All participants will receive vedolizumab together with tofacitinib for 8 weeks and will be checked for response. Participants who show a response to the treatment after 8 weeks will be treated with vedolizumab alone for an additional 44 weeks. Each participant will be followed up for at least 26 weeks after the last dose of vedolizumab.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Tuberculosis, Hepatitis, Others
      Must Not Be Taking:Immunomodulators, Immunosuppressants, NSAIDs, Others

      65 Participants Needed

      Vedolizumab + Adalimumab/Ustekinumab for Crohn's Disease

      Mansfield, Texas
      The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment. The study is conducted in two parts. In Part A, participants will receive the dual targeted treatment (vedolizumab together with either adalimumab or ustekinumab). In part B, participants will receive vedolizumab only. Part B will include participants who responded to the treatment in Part A. Each participant will be followed up for at least 26 weeks after the last dose of treatment.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Ulcerative Colitis, Abdominal Abscess, Tuberculosis, Hepatitis B, Others
      Must Not Be Taking:Anti-integrin Antibodies

      100 Participants Needed

      Lebrikizumab for Eczema

      Mansfield, Texas
      The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Chronic Disease, Liver Cirrhosis, Malignancy, Others
      Must Not Be Taking:Biologics, Immunosuppressants, Corticosteroids, Others

      200 Participants Needed

      Dupilumab for Esophagitis

      Mansfield, Texas
      This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal function, and remodeling in adults with eosinophilic esophagitis. Duration of study period (per participant) * Screening period: Up to 12 weeks before Week 0 * Randomized double-blind period: 24 weeks * Open label period: 104 weeks * Post Investigational Medicinal Product (IMP) intervention follow-up period: up to 12 weeks or until the participants switch to commercialized dupilumab, whatever comes first. There will be ten (10) site visits, and five (5) direct-to-participant IMP delivery visits (except if prohibited by local regulatory authorities or if participant is not willing. In this case, IMP will be dispensed at the study site).
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Hypereosinophilic Syndrome, Crohn's, Others
      Must Not Be Taking:Topical Corticosteroids, Dupilumab

      64 Participants Needed

      Baricitinib for Rheumatoid Arthritis

      Mansfield, Texas
      This trial compares the safety of two treatments for rheumatoid arthritis, focusing on the risk of blood clots. One treatment is baricitinib, an oral medication used for moderate to severe cases.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Cancer, Active Tuberculosis, Serious Infection, Others
      Must Be Taking:DMARDs

      1300 Participants Needed

      Benralizumab for Asthma

      Mansfield, Texas
      The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete treatment will enter 4 weeks follow-up period.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Current Smokers, Cancer, Life-threatening Asthma, Others
      Must Be Taking:Inhaled Corticosteroids, Long Acting B2-agonist

      75 Participants Needed

      MANP for High Blood Pressure

      Mansfield, Texas
      This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Secondary Hypertension, Recent MI, CHF, Others
      Must Be Taking:Antihypertensives, Diuretics, ACEi Or ARB

      120 Participants Needed

      TAK-279 for Crohn's Disease

      Mansfield, Texas
      Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate medical problems. An endoscopy will be used to check the bowel for inflammation. The participants will be treated with TAK-279 for 52 weeks (1 year). During the study, participants will visit their study clinic 15 times.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Ulcerative Colitis, Ostomy, Others

      268 Participants Needed

      ALTB-268 for Ulcerative Colitis

      Mansfield, Texas
      ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with moderately to severely active UC. The study consists of a Screening Phase, an Induction Phase, a Maintenance Phase, and an OLE.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Crohn's, Colectomy, Dysplasia, HIV, Others
      Must Be Taking:Corticosteroids, 5-ASA, Immunosuppressants

      50 Participants Needed

      AZD6793 for COPD

      Mansfield, Texas
      This Phase IIb dose-ranging study will evaluate the efficacy and safety of 3 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:40+

      Key Eligibility Criteria

      Disqualifiers:Asthma, Pulmonary Fibrosis, Heart Failure, Others
      Must Be Taking:Inhaled Maintenance Therapy

      1160 Participants Needed

      Obexelimab for Lupus

      Mansfield, Texas
      This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Lupus Nephritis, Thrombosis, Psoriasis, Others
      Must Be Taking:Corticosteroids, Antimalarials, Immunosuppressants

      190 Participants Needed

      Why Other Patients Applied

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58
      Match to a Trial

      Targeted Therapies for Crohn's Disease

      Mansfield, Texas
      Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work the same for all patients or may stop working over time. This study will evaluate the effectiveness and adverse events of targeted therapies (TaTs) for adult participants with moderate to severe CD. The medicines assessed in this study are risankizumab, ABBV-382 and lutikizumab. When participants join the study, they will be randomized into available study treatment groups. Adult participants with CD will be enrolled. Around 500 participants will be enrolled in the study at approximately 300 sites worldwide. Risankizumab and ABBV-382 are given as an injection under the skin or as an infusion into the vein. Lutikizumab is given as an injection under the skin. Each group includes a 12-week induction period, a 12-week maintenance period, and an optional long-term extension period where medication will be given after the maintenance period. There may be higher treatment burden for participants in this trial compared to their standard of care treatment without participating in this study. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, endoscopies, checking for side effects and completing questionnaires and a daily diary.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Ulcerative Colitis, Ostomy, Others
      Must Not Be Taking:P19 Inhibitors

      500 Participants Needed

      MBX 2109 for Hypoparathyroidism

      Fort Worth, Texas
      The purpose of this study is to investigate the safety and tolerability of MBX 2109 administered once weekly to patients with hypoparathyroidism.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pseudohypoparathyroidism, Cardiovascular Disease, Others
      Must Be Taking:Active Vitamin D, Calcium

      64 Participants Needed

      AZD7798 for Crohn's Disease

      Mansfield, Texas
      This is a randomised, double-blind, parallel group, placebo-controlled Phase IIa study designed to evaluate the efficacy and safety of AZD7798 in participants with moderate to severe Crohn's disease.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Other IBD, Bowel Stenoses, Cancer, Others
      Must Not Be Taking:Anti-TNF Biologics, Cyclosporine, Thalidomide, Others

      192 Participants Needed

      GS-1427 for Ulcerative Colitis

      Mansfield, Texas
      The goal of this study is to learn if GS-1427 is effective in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with GS-1427 with participants treated with placebo. The primary objective of this study is to assess the efficacy of GS-1427, compared with placebo control, in achieving clinical response at Week 12.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Crohn's Disease, Toxic Megacolon, Others
      Must Not Be Taking:Vedolizumab, Integrin Antagonists

      228 Participants Needed

      BMF-219 for Type 1 Diabetes

      Fort Worth, Texas
      This trial tests BMF-219, an oral medication that blocks a protein called menin, in people with Type 1 Diabetes. The goal is to see if it can help their insulin-producing cells work better and improve how their bodies handle sugar and fats.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:MODY, T2D, Cardiovascular Disease, Others
      Must Be Taking:Insulin

      37 Participants Needed

      Tilpisertib for Ulcerative Colitis

      Mansfield, Texas
      The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with tilpisertib fosmecarbil with participants treated with placebo. The primary objective of this study is to demonstrate the efficacy of tilpisertib fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Crohn's Disease, Opportunistic Infection, Others

      176 Participants Needed

      OM-85 for Recurrent Wheezing

      Mansfield, Texas
      This trial will test if daily OM-85 can reduce wheezing episodes in young children who often experience them. The study will focus on children aged 6 months to 5 years. OM-85 aims to help the immune system fight off infections that cause wheezing. OM-85 has been shown to reduce the risk of recurrent respiratory tract infections and wheezing attacks in children.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:6 - 72

      Key Eligibility Criteria

      Disqualifiers:Chronic Respiratory Diseases, Autoimmune, HIV, Others
      Must Not Be Taking:Steroids, Immunosuppressants

      288 Participants Needed

      Dupilumab for Eosinophilic Gastrointestinal Diseases

      Mansfield, Texas
      This trial is testing a new drug called dupilumab to see if it can help people aged 12 and older who have a condition that causes too many white blood cells to gather in their stomach and small intestine, leading to inflammation and damage. The study will compare the effects of dupilumab to another treatment and will also look at side effects and how the body reacts to the drug.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Weight < 40 Kg, Helicobacter Pylori, Crohn's, Others

      22 Participants Needed

      Oral NX-13 for Ulcerative Colitis

      Mansfield, Texas
      This trial is testing a new treatment for people with moderate to severe ulcerative colitis. The goal is to see if this treatment can reduce inflammation and improve symptoms. The study includes a period to monitor the effects over time.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Severe Colitis, Crohn's, Toxic Megacolon, Others

      80 Participants Needed

      Linaclotide for Pediatric Constipation

      Mansfield, Texas
      This trial tests linaclotide, a medication that may help young children with constipation by making their stools softer and easier to pass. The study involves children aged 6 months to less than 2 years who struggle with constipation.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:6 - 23

      Key Eligibility Criteria

      Disqualifiers:Celiac, Cystic Fibrosis, Hypothyroidism, Others
      Must Not Be Taking:Laxatives, Suppositories, Enemas

      19 Participants Needed

      1234...8

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do clinical trials in Burleson, TX pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do clinical trials in Burleson, TX work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Burleson, TX 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Burleson, TX is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Burleson, TX several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a medical study in Burleson, TX?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest clinical trials in Burleson, TX?

      Most recently, we added Pumitamig + Chemotherapy for Colorectal Cancer, Retatrutide for Obesity and Atumelnant for Congenital Adrenal Hyperplasia to the Power online platform.

      What do the "Power Preferred" and "SuperSite" badges mean?

      We recognize research clinics with these awards when they are especially responsive to patients who apply through the Power online platform. SuperSite clinics are research sites recognized for a high standard of rapid and thorough follow-up with patient applicants. Meanwhile, Power Preferred clinics are the top 20 across the entire Power platform, recognized for their absolute top patient experience.

      Which clinics have received Power Preferred and SuperSite awards in Burleson, TX?

      The clinics in Burleson, TX currently recognized as Power Preferred are: North Texas Clinical Trials in Fort Worth, Texas North Texas Clinical Trials in Fort Worth, Texas

      Popular Searches

      By Condition

      Depression Clinical Trials in Texas

      Anxiety Clinical Trials in Texas

      Schizophrenia Clinical Trials in Texas

      ADHD Clinical Trials in Texas

      Bipolar Disorder Clinical Trials in Texas

      Multiple Sclerosis Clinical Trials in Texas

      Autism Clinical Trials in Texas

      Treatment Resistant Depression Clinical Trials in Texas

      Borderline Personality Disorder Clinical Trials in Texas

      Social Anxiety Disorder Clinical Trials in Texas

      Parkinson's Disease Clinical Trials in Texas

      Alzheimer's Disease Clinical Trials in Texas

      By Location

      Clinical Trials near Houston, TX

      Clinical Trials near Dallas, TX

      Clinical Trials near San Antonio, TX

      Clinical Trials near Austin, TX

      Clinical Trials near Fort Worth, TX

      Clinical Trials near Plano, TX

      Clinical Trials near Tyler, TX

      Clinical Trials near El Paso, TX

      Clinical Trials near Lubbock, TX

      Clinical Trials near Galveston, TX

      Clinical Trials near Temple, TX

      Clinical Trials near Arlington, TX

      Other People Viewed

      By Subject

      Top Clinical Trials near Tyler, TX

      Top Clinical Trials near Kerrville, TX

      Top Clinical Trials near Huntsville, TX

      Top Clinical Trials near Irving, TX

      Top Clinical Trials near Greenville, TX

      Top Clinical Trials near Fredericksburg, TX

      Top Clinical Trials near Duncanville, TX

      Top Clinical Trials near Corsicana, TX

      Top Clinical Trials near Denison, TX

      Top Clinical Trials near Brownsville, TX

      Top Clinical Trials near Beaumont, TX

      Top Clinical Trials near Amarillo, TX

      By Trial

      Cancer Screening Methods for Colorectal and Liver Cancer

      Squatting Assist Device for Constipation

      Trazodone for Early Alzheimer's Disease

      Proton Beam Radiation Therapy for Brain Tumor

      Nurse Follow-Up Care for Post-ICU Recovery

      [212Pb]VMT-alpha-NET for Neuroendocrine Tumors

      F/TAF for HIV Pre-Exposure Prophylaxis

      Abiraterone + Niclosamide + Prednisone for Prostate Cancer

      Talazoparib for Breast Cancer

      Dapagliflozin for Heart Attack Recovery

      Entinostat + Aldesleukin for Kidney Cancer

      Percutaneous Ring Annuloplasty for Tricuspid Regurgitation

      Related Searches

      Top Clinical Trials near Burlington, VT

      Top Clinical Trials near Butte, MT

      Top Clinical Trials near Cadillac, MI

      Sevabertinib for Liver Dysfunction

      FG-3246 for Prostate Cancer

      Smartwatch and Exercise for Obesity

      Avelumab Combinations for Bladder Cancer

      N-Acetyl Cysteine + Corticosteroids for Lung Cancer

      Cochlear Implant for Unilateral Hearing Loss Post-Surgery

      Virtual Reality Therapy for Cancer-Related Symptoms

      Rectus Sheath Block for Gynecologic Surgery

      Dendritic Cell Vaccine + Pembrolizumab for Brain Metastasis from Breast Cancer